نتائج البحث - "Guise, Christopher P."

1

دورية أكاديمية

Use of an optimised enzyme/prodrug combination for Clostridia directed enzyme prodrug therapy induces a significant growth delay in necrotic tumours

المؤلفون: Mowday, Alexandra M., Dubois, Ludwig J., Kubiak, Aleksandra M., Chan-Hyams, Jasmine V. E., Guise, Christopher P., Ashoorzadeh, Amir, Lambin, Philippe, Ackerley, David F., Smaill, Jeff B., Minton, Nigel P., Theys, Jan, Patterson, Adam V.

المصدر: Mowday , A M , Dubois , L J , Kubiak , A M , Chan-Hyams , J V E , Guise , C P , Ashoorzadeh , A , Lambin , P , Ackerley , D F , Smaill , J B , Minton , N P , Theys , J & Patterson , A V 2022 , ' Use of an optimised enzyme/prodrug combination for Clostridia directed enzyme prodrug therapy induces a significant growth delay in necrotic tumours ' , Cancer Gene Therapy , vol. 29 , no. 2 , pp. 178-188 . https://doi.org/10.1038/s41417-021-00296-7Test

وصف الملف: application/pdf

الإتاحة: https://doi.org/10.1038/s41417-021-00296-7Test
https://cris.maastrichtuniversity.nl/en/publications/df7cb783-c7d9-475e-9337-a77f79540da8Test
https://cris.maastrichtuniversity.nl/ws/files/63828225/Dubois_2021_Use_of_an_optimised_enzymeprodrug_combination_for_Clostridia.pdfTest

View record in BASE

2

دورية أكاديمية

Design and Biological Evaluation of Piperazine-Bearing Nitrobenzamide Hypoxia/GDEPT Prodrugs: The Discovery of CP-506.

المؤلفون: Ashoorzadeh, Amir, Mowday, Alexandra M., Abbattista, Maria R., Guise, Christopher P., Bull, Matthew R., Silva, Shevan, Patterson, Adam V., Smaill, Jeff B.

المصدر: ACS Medicinal Chemistry Letters; 11/9/2023, Vol. 14 Issue 11, p1517-1523, 7p

3

دورية أكاديمية

Selectively Targeting Tumor Hypoxia with the Hypoxia-Activated Prodrug CP-506

المصدر: van der Wiel , A M A , Jackson-Patel , V , Niemans , R , Yaromina , A , Liu , E , Marcus , D , Mowday , A M , Lieuwes , N G , Biemans , R , Lin , X , Fu , Z , Kumara , S , Jochems , A , Ashoorzadeh , A , Anderson , R F , Hicks , K O , Bull , M R , Abbattista , M R , Guise , C P , Deschoemaeker , S , Thiolloy , S , Heyerick , A , ....

مصطلحات موضوعية: PHASE-I, MUSTARD, PR-104A, COMBINATION, TH-302, IDENTIFICATION, REPAIR, OXIDOREDUCTASE, EVOFOSFAMIDE, DOXORUBICIN

الإتاحة: https://doi.org/10.1158/1535-7163.MCT-21-0406Test
https://cris.maastrichtuniversity.nl/en/publications/88b13f8c-1c7d-4e61-8dfc-034eda5a4a38Test

View record in BASE

4

دورية أكاديمية

Restoring tumour selectivity of the bioreductive prodrug pr-104 by developing an analogue resistant to aerobic metabolism by human aldo-keto reductase 1c3

المؤلفون: Abbattista, Maria R., Ashoorzadeh, Amir, Guise, Christopher P., Mowday, Alexandra M., Mittra, Rituparna, Silva, Shevan, Hicks, Kevin O., Bull, Matthew R., Jackson-Patel, Victoria, Lin, Xiaojing, Prosser, Gareth A., Lambie, Neil K., Dachs, Gabi U., Ackerley, David F., Smaill, Jeff B., Patterson, Adam V.

المصدر: Abbattista , M R , Ashoorzadeh , A , Guise , C P , Mowday , A M , Mittra , R , Silva , S , Hicks , K O , Bull , M R , Jackson-Patel , V , Lin , X , Prosser , G A , Lambie , N K , Dachs , G U , Ackerley , D F , Smaill , J B & Patterson , A V 2021 , ' Restoring tumour selectivity of the bioreductive prodrug pr-104 by developing an analogue resistant to aerobic metabolism by human aldo-keto reductase 1c3 ' ....

مصطلحات موضوعية: Aldo-keto reductase 1C3, Bioreductive prodrug, Cytochrome P450 oxidoreductase, Hypoxia-activated prodrug, Myelotoxicity, Orthologues, PR-104, /dk/atira/pure/subjectarea/asjc/1300/1313, name=Molecular Medicine, /dk/atira/pure/subjectarea/asjc/3000/3003, name=Pharmaceutical Science, /dk/atira/pure/subjectarea/asjc/3000/3002, name=Drug Discovery

وصف الملف: application/pdf

العلاقة: https://discovery.dundee.ac.uk/en/publications/c3a01da2-b52f-47d5-bf2b-f3e135947b21Test

الإتاحة: https://doi.org/10.3390/ph14121231Test
https://discovery.dundee.ac.uk/en/publications/c3a01da2-b52f-47d5-bf2b-f3e135947b21Test
https://discovery.dundee.ac.uk/ws/files/70864772/pharmaceuticals_14_01231_v2.pdfTest
http://www.scopus.com/inward/record.url?scp=85120404060&partnerID=8YFLogxKTest

View record in BASE

5

دورية أكاديمية

Hypoxia-activated prodrugs and (lack of) clinical progress:The need for hypoxia-based biomarker patient selection in phase III clinical trials

المؤلفون: Spiegelberg, Linda, Houben, Ruud, Niemans, Raymon, de Ruysscher, Dirk, Yaromina, Ala, Theys, Jan, Guise, Christopher P., Smaill, Jeffrey B., Patterson, Adam V., Lambin, Philippe, Dubois, Ludwig J.

المصدر: Spiegelberg , L , Houben , R , Niemans , R , de Ruysscher , D , Yaromina , A , Theys , J , Guise , C P , Smaill , J B , Patterson , A V , Lambin , P & Dubois , L J 2019 , ' Hypoxia-activated prodrugs and (lack of) clinical progress : The need for hypoxia-based biomarker patient selection in phase III clinical trials ' , Clinical and Translational Radiation Oncology , vol. 15 , pp. 62-69 . https://doi.org/10.1016/j.ctro.2019.01.005Test

مصطلحات موضوعية: Hypoxia-activated prodrugs, Phase III clinical trial, Biomarker, Hypoxia, C P450 REDUCTASE, POSITRON-EMISSION-TOMOGRAPHY, SQUAMOUS-CELL CARCINOMAS, OXYGEN-ENHANCED MRI, TUMOR HYPOXIA, ANTITUMOR-ACTIVITY, NECK-CANCER, LUNG-CANCER, EXTRAVASCULAR TRANSPORT, EVOFOSFAMIDE TH-302

الإتاحة: https://doi.org/10.1016/j.ctro.2019.01.005Test
https://cris.maastrichtuniversity.nl/en/publications/1fbf9033-8075-4655-9efb-1632d138d1a5Test

View record in BASE

6

دورية أكاديمية

Engineering a Multifunctional Nitroreductase for Improved Activation of Prodrugs and PET Probes for Cancer Gene Therapy

المؤلفون: Copp, Janine N., Mowday, Alexandra M., Williams, Elsie M., Guise, Christopher P., Ashoorzadeh, Amir, Sharrock, Abigail V., Flanagan, Jack U., Smaill, Jeff B., Patterson, Adam V., Ackerley, David F.

المساهمون: Royal Society of New Zealand, Health Research Council of New Zealand, Genesis Oncology Trust, Cancer Society of New Zealand, Tertiary Education Commission, University of Auckland

المصدر: Cell Chemical Biology ; volume 24, issue 3, page 391-403 ; ISSN 2451-9456

مصطلحات موضوعية: Clinical Biochemistry, Drug Discovery, Pharmacology, Molecular Biology, Molecular Medicine, Biochemistry

الإتاحة: https://doi.org/10.1016/j.chembiol.2017.02.005Test
https://api.elsevier.com/content/article/PII:S2451945617300351?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2451945617300351?httpAccept=text/plainTest

View record in BASE

7

دورية أكاديمية

Advancing Clostridia to Clinical Trial: Past Lessons and Recent Progress

المؤلفون: Mowday, Alexandra M., Guise, Christopher P., Ackerley, David F., Minton, Nigel P., Lambin, Philippe, Dubois, Ludwig J., Theys, Jan, Smaill, Jeff B., Patterson, Adam V.

المصدر: Mowday , A M , Guise , C P , Ackerley , D F , Minton , N P , Lambin , P , Dubois , L J , Theys , J , Smaill , J B & Patterson , A V 2016 , ' Advancing Clostridia to Clinical Trial: Past Lessons and Recent Progress ' , Cancers , vol. 8 , no. 7 , 63 . https://doi.org/10.3390/cancers8070063Test

مصطلحات موضوعية: Clostridium, cancer, gene therapy, imaging, prodrug, radiotherapy, immunotherapy

الإتاحة: https://doi.org/10.3390/cancers8070063Test
https://cris.maastrichtuniversity.nl/en/publications/4edf4db6-0e17-45a4-8580-ffec49d3b8c0Test

View record in BASE